Bioaffinity Technologies, Inc. (BIAF) - 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated March 6, 2024, details a material definitive agreement entered into by Bioaffinity Technologies, Inc. (the "Company"). The Company, an emerging growth company incorporated in Delaware, announced a registered direct offering and concurrent private placement of securities to four institutional investors.
Key Financial Metrics and Transaction Details
- Gross Proceeds: The Company expects to receive approximately $2.5 million in aggregate gross proceeds from the transaction, before deducting fees and offering expenses.
- Securities Issued:
- 1,600,000 shares of Common Stock (Registered Direct Offering).
- Warrants to purchase 1,600,000 shares of Common Stock (Private Placement) with an exercise price of $1.64.
- Placement Agent Compensation: Wallachbeth Capital LLC received a cash fee of 9.0% of gross proceeds and a warrant to purchase 32,000 shares (2.0% of the offering) at an exercise price of $1.64.
- Impact on Existing Warrants: Upon issuance, the exercise price of warrants from the Company's initial public offering was reduced to $3.0625.
Material Changes and Covenants
The filing discloses significant covenants restricting the Company's ability to raise capital in the near term:
- Market Stand-Off: The Company is prohibited from issuing Common Stock or equivalents for 60 days following the closing, with limited exceptions.
- Variable Rate Transaction Ban: The Company cannot enter into variable rate transactions for 12 months post-closing, though the ban on at-the-market offerings and equity lines of credit expires after six months.
- Lock-Up Agreements: The CEO and all directors are subject to a 60-day lock-up agreement preventing the sale or transfer of Company securities.
- Participation Rights: Purchasers have the right to participate in subsequent financings for up to nine months to maintain their pro-rata ownership percentage.
Outlook, Risks, and Contingencies
Stockholder Approval Requirement: The Common Warrants are not exercisable until the effective date of stockholder approval for the issuance of the underlying shares. Major stockholders holding over 21% of outstanding shares have signed a Support Agreement to vote in favor of this proposal.
Warrant Terms and Risks:
- Expiration: Warrants expire on the fifth anniversary of the stockholder approval date.
- Cashless Exercise: If a registration statement is not effective 90 days post-closing, holders may elect cashless exercise.
- Beneficial Ownership Limit: Exercise is restricted if the holder would own more than 4.99% (or 9.99% upon election) of outstanding shares.
- Fundamental Transaction: In the event of a merger or acquisition, holders may require the Company to redeem unexercised warrants for cash based on the Black Scholes Value.
Investor Verification Checklist
- Verify the closing date and actual net proceeds received after deducting the 9.0% placement fee and other expenses.
- Confirm the date and outcome of the stockholder vote required to enable warrant exercise.
- Review the updated capitalization table to assess the dilution impact of the 1.6 million new shares and the 1.6 million warrant shares.
- Monitor the Company's compliance with the 60-day market stand-off and 12-month variable rate transaction restrictions.
- Check the status of the registration statement filed to register the resale of warrant shares.